Cargando…

A psychometric analysis of outcome measures in peripheral spondyloarthritis

OBJECTIVES: To assess the discriminatory capacity of various outcome measures and response criteria in patients with peripheral spondyloarthritis (pSpA). METHODS: Data originated from two randomised controlled trials, ABILITY-2 and Tnf Inhibition in PEripheral SpondyloArthritis (TIPES). Continuous o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Turina, Maureen C, Ramiro, Sofia, Baeten, Dominique L, Mease, Philip, Paramarta, Jacqueline E, Song, In-Ho, Pangan, Aileen L, Landewé, Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2016
Materias:	Clinical and Epidemiological Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4941177/ https://www.ncbi.nlm.nih.gov/pubmed/26245756 http://dx.doi.org/10.1136/annrheumdis-2014-207235

Ejemplares similares

Calprotectin (S100A8/9) as serum biomarker for clinical response in proof-of-concept trials in axial and peripheral spondyloarthritis
por: Turina, Maureen C, et al.
Publicado: (2014)

Synovial Tissue Response to Treatment with TNF Blockers in Peripheral Spondyloarthritis
por: Paramarta, Jacqueline E, et al.
Publicado: (2011)

Serum biomarkers to predict clinical response in proof-of-concept trials in spondyloarthritis
por: Turina, Maureen, et al.
Publicado: (2011)

Adalimumab serum levels and antidrug antibodies towards adalimumab in peripheral spondyloarthritis: no association with clinical response to treatment or with disease relapse upon treatment discontinuation
por: Paramarta, Jacqueline E, et al.
Publicado: (2014)

A proof-of-concept study with the tyrosine kinase inhibitor nilotinib in spondyloarthritis
por: Paramarta, Jacqueline E., et al.
Publicado: (2016)

Long-term efficacy and predictors of remission following adalimumab treatment in peripheral spondyloarthritis: 3-year results from ABILITY-2
por: Van den Bosch, Filip, et al.
Publicado: (2018)

Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)
por: Sieper, Joachim, et al.
Publicado: (2013)

Randomized Controlled Trial of Adalimumab in Patients With Nonpsoriatic Peripheral Spondyloarthritis
por: Mease, Philip, et al.
Publicado: (2015)

Peripheral disease contributes significantly to the level of disease activity in axial spondyloarthritis
por: de Winter, Janneke J, et al.
Publicado: (2019)

Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis
por: Schoels, M M, et al.
Publicado: (2014)

Serum inflammatory biomarkers fail to identify early axial spondyloarthritis: results from the SpondyloArthritis Caught Early (SPACE) cohort
por: Turina, Maureen C, et al.
Publicado: (2017)

Sacroiliac radiographic progression in recent onset axial spondyloarthritis: the 5-year data of the DESIR cohort
por: Dougados, Maxime, et al.
Publicado: (2017)

Frequency of Axial Spondyloarthritis Diagnosis Among Patients Seen by US Rheumatologists for Evaluation of Chronic Back Pain
por: Deodhar, Atul, et al.
Publicado: (2016)

Non-radiographic axial spondyloarthritis patients without initial evidence of inflammation may develop objective inflammation over time
por: Baraliakos, Xenofon, et al.
Publicado: (2017)

COVID-19-induced hyperinflammation, immunosuppression, recovery and survival: how causal inference may help draw robust conclusions
por: Landewé, Robert B M, et al.
Publicado: (2021)

Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: a meta-analysis
por: de Winter, Janneke J., et al.
Publicado: (2016)

Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study
por: Landewé, R, et al.
Publicado: (2014)

Three handy tips and a practical guide to improve your propensity score models
por: Bergstra, Sytske Anne, et al.
Publicado: (2019)

Cardiovascular and selected comorbidities in early arthritis and early spondyloarthritis, a comparative study: results from the ESPOIR and DESIR cohorts
por: Gherghe, Ana Maria, et al.
Publicado: (2015)

Development and psychometric validation of a patient-reported outcome measure to assess fears in rheumatoid arthritis and axial spondyloarthritis: the Fear Assessment in Inflammatory Rheumatic diseases (FAIR) questionnaire
por: Gossec, Laure, et al.
Publicado: (2018)

Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases
por: Burmester, G R, et al.
Publicado: (2009)

Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis
por: Sieper, Joachim, et al.
Publicado: (2011)

A single determination of C-reactive protein does not suffice to declare a patient with a diagnosis of axial spondyloarthritis ‘CRP-negative’
por: Landewé, Robert, et al.
Publicado: (2018)

How do clinical and socioeconomic factors impact on work disability in early axial spondyloarthritis? Five-year data from the DESIR cohort
por: Nikiphorou, Elena, et al.
Publicado: (2021)

Determinants of the patient global assessment of well-being in early axial spondyloarthritis: 5-year longitudinal data from the DESIR cohort
por: Hirano, Fumio, et al.
Publicado: (2020)

ASAS40 and ASDAS clinical responses in the ABILITY-1 clinical trial translate to meaningful improvements in physical function, health-related quality of life and work productivity in patients with non-radiographic axial spondyloarthritis
por: van der Heijde, Désirée, et al.
Publicado: (2016)

Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis
por: Gaujoux-Viala, Cécile, et al.
Publicado: (2014)

Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension
por: Keystone, Edward, et al.
Publicado: (2014)

Biological DMARDs and disease modification in axial spondyloarthritis: a review through the lens of causal inference
por: Sepriano, Alexandre, et al.
Publicado: (2021)

Elevated calprotectin levels reveal bowel inflammation in spondyloarthritis
por: Cypers, H, et al.
Publicado: (2016)

IL-17 in spondyloarthritis: is the T-party over?
por: Yeremenko, Nataliya, et al.
Publicado: (2011)

Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial
por: van der Heijde, Désirée, et al.
Publicado: (2018)

Referral Patterns, Diagnosis, and Disease Management of Patients With Axial Spondyloarthritis: Results of an International Survey
por: van der Heijde, Désirée, et al.
Publicado: (2014)

Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study
por: Mease, Philip, et al.
Publicado: (2018)

Spondyloarthritis in the Democratic Republic of the Congo: a prospective hospital-based study
por: Lebughe, Pierrot, et al.
Publicado: (2018)

Evaluation of the change in structural radiographic sacroiliac joint damage after 2 years of etanercept therapy (EMBARK trial) in comparison to a contemporary control cohort (DESIR cohort) in recent onset axial spondyloarthritis
por: Dougados, Maxime, et al.
Publicado: (2018)

Age at onset in axial spondyloarthritis around the world: data from the Assessment in SpondyloArthritis international Society Peripheral Involvement in Spondyloarthritis study
por: Boel, Anne, et al.
Publicado: (2021)

Are gender-specific approaches needed in diagnosing early axial spondyloarthritis? Data from the SPondyloArthritis Caught Early cohort
por: Ortolan, Augusta, et al.
Publicado: (2018)

Axial Disease in Psoriatic Arthritis study: defining the clinical and radiographic phenotype of psoriatic spondyloarthritis
por: Jadon, Deepak R, et al.
Publicado: (2017)

Is a positive family history of spondyloarthritis relevant for diagnosing axial spondyloarthritis once HLA-B27 status is known?
por: van Lunteren, Miranda, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_lq7qj544qucki5vudq0mel0gti